Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03596567
Previous Study | Return to List | Next Study

Glasdegib Renal Impairment Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03596567
Recruitment Status : Completed
First Posted : July 24, 2018
Last Update Posted : September 27, 2018
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE April 2, 2018
First Posted Date  ICMJE July 24, 2018
Last Update Posted Date September 27, 2018
Actual Study Start Date  ICMJE May 17, 2018
Actual Primary Completion Date August 28, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 12, 2018)
  • Maximum Observed Plasma Concentration (Cmax) [ Time Frame: 6 days ]
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] [ Time Frame: 6 days ]
    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03596567 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 12, 2018)
  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]). [ Time Frame: 34 days ]
    concomitant medication and adverse event monitoring.
  • PR/ECGs [ Time Frame: 34 days ]
    PR interval (msec),
  • Hematology Lab Panel [ Time Frame: 34 days ]
    Platelet count (10^3/mm^3)
  • BUN /Chemistry Lab Panel [ Time Frame: 34 days ]
    BUN (mg/dL)
  • pH/Urinalysis Lab Panel [ Time Frame: 34 days ]
    pH (no unit)
  • Blood Pressure [ Time Frame: 34 days ]
    Supine Systolic and Diastolic blood pressure (mm of Hg). Reported as Systolic/Diastolic
  • Pulse Rate [ Time Frame: 34 days ]
    Pulse Rate will be reported in beats per minute.
  • ECGs [ Time Frame: 34 days ]
    Heart Rate (beats per minute)
  • Hemoglobin /Hematology Lab Panel [ Time Frame: 34 days ]
    Hemoglobin (g/dL)
  • Hematology Lab Panel [ Time Frame: 34 days ]
    Hematocrit (%)
  • Hematology Lab Panel [ Time Frame: 34 days ]
    RBC Count (10^6/mm^3)
  • Hematology Lab Panel [ Time Frame: 34 days ]
    MCV (femto Liters)
  • Hematology Lab Panel [ Time Frame: 34 days ]
    MCH (pictograms/cell)
  • Potassium/Chemistry Lab Panel [ Time Frame: 34 days ]
    Potassium (Meq/L)
  • AST/Chemistry Lab Panel [ Time Frame: 34 days ]
    AST (U/L)
  • Albumin/Chemistry Lab Panel [ Time Frame: 34 days ]
    Albumin (g/dL)
  • MCHC/Hematology Lab Panel [ Time Frame: 34 days ]
    MCHC (10^3/mm^3)
  • WBC count/Hematology Lab Panel [ Time Frame: 34 days ]
    WBC count (10^3/mm^3),
  • Total neutrophils/Hematology Lab Panel [ Time Frame: 34 days ]
    Total neutrophils (Abs)(10^3/mm^3),
  • Eosinophils/Hematology Lab Panel [ Time Frame: 34 days ]
    Eosinophils (Abs)(10^3/mm^3
  • Monocytes/Hematology Lab Panel [ Time Frame: 34 days ]
    Monocytes (Abs)(10^3/mm^3)
  • Basophils/Hematology Lab Panel [ Time Frame: 34 days ]
    Basophils (Abs) (10^3/mm^3)
  • Lymphocytes/Hematology Lab Panel [ Time Frame: 34 days ]
    Lymphocytes (Abs) (10^3/mm^3)
  • Total Protein/Chemistry Lab Panel [ Time Frame: 34 days ]
    Total Protein (g/dL)
  • ALT/Chemistry Lab Panel [ Time Frame: 34 days ]
    ALT (U/L)
  • Alkaline Phosphate/Chemistry Lab Panel [ Time Frame: 34 days ]
    Alkaline Phosphate (U/L)
  • Sodium/Chemistry Lab Panel [ Time Frame: 34 days ]
    Sodium (Meq/L)
  • Chloride/Chemistry Lab Panel [ Time Frame: 34 days ]
    Chloride (Meq/L)
  • Creatinine/Chemistry Lab Panel [ Time Frame: 34 days ]
    Creatinine (mg/dL),
  • Glucose/Chemistry Lab Panel [ Time Frame: 34 days ]
    Glucose (mg/dL),
  • Calcium/Chemistry Lab Panel [ Time Frame: 34 days ]
    Calcium (mg/dL),
  • Total Bilirubin/Chemistry Lab Panel [ Time Frame: 34 days ]
    Total Bilirubin (mg/dL),
  • Uric acid/Chemistry Lab Panel [ Time Frame: 34 days ]
    Uric acid (mg/dL)
  • Magnesium/Chemistry Lab Panel [ Time Frame: 34 days ]
    Magnesium (mg/dL)
  • QTc/ECGs [ Time Frame: 34 days ]
    QTc interval (msec)
  • QRS/ECGs [ Time Frame: 34 days ]
    QRS interval (msec)
  • Glucose/Urinalysis Lab Panel [ Time Frame: 34 days ]
    Glucose (qual) (no unit)
  • Protein/Urinalysis Lab Panel [ Time Frame: 34 days ]
    Protein (qual) (no unit)
  • Blood/Urinalysis Lab Panel [ Time Frame: 34 days ]
    Blood (qual) (no units)
  • Ketones/Urinalysis Lab Panel [ Time Frame: 34 days ]
    Ketones (no units)
  • Nitrites/Urinalysis Lab Panel [ Time Frame: 34 days ]
    Nitrites (no units)
  • Leukocyte /Urinalysis Lab Panel [ Time Frame: 34 days ]
    Leukocyte esterase (no units)
  • Urobilinogen/Urinalysis Lab Panel [ Time Frame: 34 days ]
    Urobilinogen (no unit)
  • Urine bilirubin/Urinalysis Lab Panel [ Time Frame: 34 days ]
    Urine bilirubin (no unit)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Glasdegib Renal Impairment Study
Official Title  ICMJE A Phase 1, Open-label, Single Dose, Parallel Group Study To Evaluate The Pharmacokinetics Of Glasdegib (Pf-04449913) In Subjects With Impaired Renal Function
Brief Summary The goal of this study is to administer single dose (100 mg) glasdegib tablet to subjects with normal, moderate and severe renal impairment and estimate the effect, if any, of this renal impairment on glasdegib pharmacokinetics.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Renal Impairment
Intervention  ICMJE
  • Drug: Glasdegib single 100 mg dose in normal healthy subjects
    A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
  • Drug: Glasdegib single 100 mg dose in moderate renal impairment subjects
    A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
  • Drug: Glasdegib single 100 mg dose in severe renal impairment subjects
    A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
Study Arms  ICMJE
  • Experimental: Normal Renal Function Group
    Subjects with estimated glomerular filtration rate (eGFR) of => 90 ml/min
    Intervention: Drug: Glasdegib single 100 mg dose in normal healthy subjects
  • Experimental: Moderate Renal Impairment Group
    Subjects with estimated glomerular filtration rate (eGFR) of => 30ml/min and < 60 ml/min
    Intervention: Drug: Glasdegib single 100 mg dose in moderate renal impairment subjects
  • Experimental: Severe Renal Impairment Group
    Subjects with estimated glomerular filtration rate (eGFR) of < 30 ml/min and not requiring dialysis
    Intervention: Drug: Glasdegib single 100 mg dose in severe renal impairment subjects
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 12, 2018)
18
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 19, 2018
Actual Primary Completion Date August 28, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Healthy female subjects of non child bearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 75 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests.
  2. Female subjects of nonchildbearing potential must meet at least 1 of the following criteria:

    1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state;
    2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
    3. Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations) are considered to be of childbearing potential.
  3. Body mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).
  4. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
  5. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Subjects with Normal Renal Function will Need to Meet the Following Criteria in addition -

  1. Normal renal function, eGFR=>90 mL/min, based on the MDRD equation.
  2. Matched for age (+/-10years) weight +/-15kg, and gender to subjects in the impaired renal function groups

Subjects with Impaired Renal Function will Need to Meet the Following Criteria in Addition to Those Above

  1. Good general health commensurate with the population with chronic kidney disease (renal impairment). 'Health' is defined as no clinically relevant abnormalities (with the exception of hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease, etc. as long as, in the opinion of the investigator, the subject is medically stable, is on a stable drug regimen and can abide by the meals and dietary restrictions outlined in protocol identified by a detailed medical history, full physical examination, measurement of pulse rate and 12 lead ECG as well as clinical laboratory tests (except serum creatinine and eGFR).
  2. Stable drug regimen defined as not starting a new drug or changing dosage within seven days or five half lives (whichever is longer) before dosing the study drug.
  3. Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).
  4. Meet one of the following eGFR criteria during the screening period based on the MDRD equation:

    1. Moderate renal impairment: eGFR 30 mL/min and <60 mL/min, or
    2. Severe renal impairment: eGFR <30 mL/min, but not requiring hemodialysis. For subjects in all groups, the values of serum creatinine obtained at the two screening visits should not be more than 20% different.

      Exclusion Criteria:

      -Any condition possibly affecting drug absorption (eg, gastrectomy, achlorhydria).

      Renal allograft recipients

      Urinary incontinence without catheterization.

      Concurrent use of any of the following food or drugs known to inhibit CYP3A4 (consult the Sponsor if in doubt whether a food or a drug falls into any of the above categories) within 7 days or 5 half lives (whichever is longer) prior to the dose of glasdegib, until the completion of the last PK sample collection.

      Concurrent use of any of the following food or drugs known to induce CYP3A4 (consult the Sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days or 5 half lives (whichever is longer) prior to the first dose of trial medication until the completion of the last PK sample collection.

      Pregnant female subjects; breastfeeding female subjects; fertile male subjects who are unwilling or unable to use two highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 90 days after the last dose of investigational product and, refrain from sperm donation for the duration of the Study and for at least 90 days after the last dose of investigational product.

      Subjects with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

      • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level > upper limit of normal (ULN);
      • Total bilirubin level 1.5 × ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is not greater than 0.5 mg/dL.

      For subjects with renal impairment, the following important additional criteria are:

      Subjects with other clinically significant disease that may affect the safety of the subject or that may affect the pharmacokinetics of glasdegib (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Subjects with any significant hepatic, cardiac, or pulmonary disease or subjects who are clinically nephrotic. Hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease, etc is not cause for exclusion as long as the subject is medically stable and any drugs that are administered for these conditions are not expected to interfere with the pharmacokinetics of glasdegib.

      Screening blood pressure =>180mm Hg (systolic) or>=110 mm Hg (diastolic), following at least 5 minutes of supine rest. If initial blood pressure (BP) is 180 mm Hg (systolic) or 110 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.

      Screening supine 12 lead ECG demonstrating QTcF >470 msec or a QRS interval >120 msec. If initial QTcF exceeds 470 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTcF or QRS values should be used to determine the subject's eligibility.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03596567
Other Study ID Numbers  ICMJE B1371017
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date September 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP